{"transactions":[{"id":5610,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Option (Right to buy)","published_at":"2026-08-18T21:00:16.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":false,"shares":32710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022."}],"balance_after":0,"derivative":{"exercise_price":79.02,"expiration_date":"2029-02-20","underlying":"Common Stock","underlying_shares":32710},"source":{"system":"sec-edgar","filing":"0001762951-26-000006","document":"form4-08182026_050811.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000006/form4-08182026_050811.xml","form_type":"4"}},{"id":5609,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-08-18T21:00:16.000Z","date":"2026-08-14","kind":"sale","planned":false,"acquired":false,"shares":32710,"price":250,"value":8177500.0,"ownership":{"direct":true},"balance_after":74430,"source":{"system":"sec-edgar","filing":"0001762951-26-000006","document":"form4-08182026_050811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000006/form4-08182026_050811.xml","form_type":"4"}},{"id":5608,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-08-18T21:00:16.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":true,"shares":32710,"price":79.02,"value":2584744.2,"ownership":{"direct":true},"balance_after":107140,"source":{"system":"sec-edgar","filing":"0001762951-26-000006","document":"form4-08182026_050811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000006/form4-08182026_050811.xml","form_type":"4"}},{"id":12464,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:06.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":12874,"price":232.08,"value":2987797.92,"ownership":{"direct":true},"balance_after":74430,"source":{"system":"sec-edgar","filing":"0001762951-26-000004","document":"form4-03032026_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000004/form4-03032026_060301.xml","form_type":"4"}},{"id":13226,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":20312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029."}],"balance_after":20312,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":20312},"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13225,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":87304,"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13224,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":5172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":81082,"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13223,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":4632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":75910,"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13222,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":13031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":71278,"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":21052,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-08-07T21:00:06.000Z","date":"2025-08-05","kind":"sale","planned":false,"acquired":false,"shares":10061,"price":198.59,"value":1998013.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.56 to $198.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":58247,"source":{"system":"sec-edgar","filing":"0001415889-25-021280","document":"form4-08072025_050802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925021280/form4-08072025_050802.xml","form_type":"4"}},{"id":21051,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-08-07T21:00:06.000Z","date":"2025-08-05","kind":"sale","planned":false,"acquired":false,"shares":3234.17,"price":198.27,"value":641238.8859,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.26 to $198.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This reflects shares acquired pursuant to a dividend reinvestment plan."}],"balance_after":68308,"source":{"system":"sec-edgar","filing":"0001415889-25-021280","document":"form4-08072025_050802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925021280/form4-08072025_050802.xml","form_type":"4"}},{"id":26181,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-03-04T22:00:25.000Z","date":"2025-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":11230,"price":205.02,"value":2302374.6,"ownership":{"direct":true},"balance_after":70018,"source":{"system":"sec-edgar","filing":"0001415889-25-006585","document":"form4-03042025_050318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925006585/form4-03042025_050318.xml","form_type":"4"}},{"id":28031,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Option (Right to buy)","published_at":"2025-02-18T22:00:11.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":23437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028."}],"balance_after":23437,"derivative":{"exercise_price":192.86,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":23437},"source":{"system":"sec-edgar","filing":"0001415889-25-004457","document":"form4-02182025_050205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925004457/form4-02182025_050205.xml","form_type":"4"}},{"id":28030,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:11.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":5174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":81248,"source":{"system":"sec-edgar","filing":"0001415889-25-004457","document":"form4-02182025_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925004457/form4-02182025_050205.xml","form_type":"4"}},{"id":28029,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:11.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":4634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":76074,"source":{"system":"sec-edgar","filing":"0001415889-25-004457","document":"form4-02182025_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925004457/form4-02182025_050205.xml","form_type":"4"}},{"id":28028,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:11.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":4520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":71440,"source":{"system":"sec-edgar","filing":"0001415889-25-004457","document":"form4-02182025_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925004457/form4-02182025_050205.xml","form_type":"4"}},{"id":28027,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:11.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":11017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":66920,"source":{"system":"sec-edgar","filing":"0001415889-25-004457","document":"form4-02182025_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925004457/form4-02182025_050205.xml","form_type":"4"}},{"id":42532,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-22T21:00:15.000Z","date":"2024-03-20","kind":"sale","planned":false,"acquired":false,"shares":21082,"price":176.3,"value":3716756.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.26 to $176.35, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":55903,"source":{"system":"sec-edgar","filing":"0001415889-24-008970","document":"form4-03222024_050301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588924008970/form4-03222024_050301.xml","form_type":"4"}},{"id":44469,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-01T22:50:09.000Z","date":"2024-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":16771,"price":178.99,"value":3001841.29,"ownership":{"direct":true},"balance_after":76985,"source":{"system":"sec-edgar","filing":"0001415889-24-006156","document":"form4-03012024_050303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588924006156/form4-03012024_050303.xml","form_type":"4"}},{"id":45417,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Option (Right to buy)","published_at":"2024-02-20T22:17:50.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":21433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,145 on February 15, 2025, 7,144 on February 15, 2026, and 7,144 on February 15, 2027."}],"balance_after":21433,"derivative":{"exercise_price":0,"exercise_date":"2025-02-15","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":21433},"source":{"system":"sec-edgar","filing":"0001415889-24-004423","document":"form4-02202024_100216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588924004423/form4-02202024_100216.xml","form_type":"4"}},{"id":45416,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:17:50.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":4634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":93756,"source":{"system":"sec-edgar","filing":"0001415889-24-004423","document":"form4-02202024_100216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588924004423/form4-02202024_100216.xml","form_type":"4"}},{"id":45415,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:17:50.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":4520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":89122,"source":{"system":"sec-edgar","filing":"0001415889-24-004423","document":"form4-02202024_100216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588924004423/form4-02202024_100216.xml","form_type":"4"}},{"id":45414,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:17:50.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":6042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":84602,"source":{"system":"sec-edgar","filing":"0001415889-24-004423","document":"form4-02202024_100216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588924004423/form4-02202024_100216.xml","form_type":"4"}},{"id":45413,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:17:50.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":22657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":78560,"source":{"system":"sec-edgar","filing":"0001415889-24-004423","document":"form4-02202024_100216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588924004423/form4-02202024_100216.xml","form_type":"4"}},{"id":49140,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-12-28T22:00:12.000Z","date":"2023-12-26","kind":"sale","planned":false,"acquired":false,"shares":2912,"price":154.72,"value":450544.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.72 to $154.73, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":55903,"source":{"system":"sec-edgar","filing":"0001415889-23-016990","document":"form4-12282023_051202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588923016990/form4-12282023_051202.xml","form_type":"4"}},{"id":106577,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Enterprise Innovation"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-03T21:51:54.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":2355,"price":85.42,"value":201164.1,"ownership":{"direct":true},"balance_after":15149,"source":{"system":"sec-edgar","filing":"0001179110-20-002852","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000117911020002852/edgar.xml","form_type":"4"}},{"id":107140,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Enterprise Innovation"}}],"security":"Option (right to buy)","published_at":"2020-02-24T23:04:00.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":72013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,005 on February 20, 2021, 24,004 on February 20, 2022, and 24,004 on February 20, 2023."}],"balance_after":72013,"derivative":{"exercise_price":93.5,"exercise_date":"2021-02-20","expiration_date":"2030-02-19","underlying":"Common Stock","underlying_shares":72013},"source":{"system":"sec-edgar","filing":"0001179110-20-002136","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000117911020002136/edgar.xml","form_type":"4"}},{"id":107139,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Enterprise Innovation"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:04:00.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":5316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":17504,"source":{"system":"sec-edgar","filing":"0001179110-20-002136","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000117911020002136/edgar.xml","form_type":"4"}},{"id":109357,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Enterprise Innovation"}}],"security":"Common stock, $0.01 par value","published_at":"2020-01-06T21:28:43.000Z","date":"2020-01-02","kind":"tax_withholding","acquired":false,"shares":902,"price":88.54,"value":79863.08,"ownership":{"direct":true},"balance_after":12188,"source":{"system":"sec-edgar","filing":"0001179110-20-000295","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000117911020000295/edgar.xml","form_type":"4"}},{"id":113466,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Enterprise Innovation"}}],"security":"Common stock, $0.01 par value","published_at":"2019-08-30T20:08:01.000Z","date":"2019-08-29","kind":"purchase","acquired":true,"shares":7525,"price":66.187,"value":498057.175,"ownership":{"direct":true},"balance_after":13090,"source":{"system":"sec-edgar","filing":"0001179110-19-009960","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000117911019009960/edgar.xml","form_type":"4"}},{"id":119506,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Enterprise Innovation"}}],"security":"Option (right to buy)","published_at":"2019-02-22T22:17:19.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":32710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022."}],"balance_after":32710,"derivative":{"exercise_price":79.02,"exercise_date":"2020-02-21","expiration_date":"2029-02-20","underlying":"Common Stock","underlying_shares":32710},"source":{"system":"sec-edgar","filing":"0001179110-19-002362","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000117911019002362/edgar.xml","form_type":"4"}},{"id":121351,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Enterprise Innovation"}}],"security":"Common Stock, $0.01 par value","published_at":"2019-01-04T21:52:05.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":5565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in annual increments of 1,855 on 01/02/2020, 1,855 on 01/02/2021, and 1,855 on 01/02/2022, and include the right to have stock withheld for tax purposes."}],"balance_after":5565,"source":{"system":"sec-edgar","filing":"0001179110-19-000444","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000117911019000444/edgar.xml","form_type":"4"}}]}